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Abstract
Minimal residual disease, or MRD, is an important prognostic indicator in childhood acute lymphoblastic leukemia. In ALL-IC-
BFM 2002 study, we employed a standardized method of flow cytometry MRD monitoring for multiple centers
internationally using uniformed gating, and determined the relevant MRD-based risk stratification strategies in our local
patient cohort. We also evaluated a novel method of PCR MRD quantitation using peripheral blood plasma. For the bone
marrow flow MRD study, patients could be stratified into 3 risk groups according to MRD level using a single time-point at
day-15 (Model I) (I-A: ,0.1%, I-B: 0.1–10%, I-C: .10%), or using two time-points at day-15 and day-33 (Model II) (II-A: day-
15,10% and day-33,0.01%, II-B: day-15$10% or day-33$0.01% but not both, II-C: day-15$10% and day-33$0.01%),
which showed significantly superior prediction of relapse (p = .00047 and ,0.0001 respectively). Importantly, patients with
good outcome (frequency: 56.0%, event-free survival: 90.1%) could be more accurately predicted by Model II. In peripheral
blood plasma PCR MRD investigation, patients with day-15-MRD$1024 were at a significantly higher risk of relapse
(p = 0.0117). By multivariate analysis, MRD results from both methods could independently predict patients’ prognosis, with
20–35-fold increase in risk of relapse for flow MRD I-C and II-C respectively, and 5.8-fold for patients having plasma MRD of
$1024. We confirmed that MRD detection by flow cytometry is useful for prognostic evaluation in our Chinese cohort of
childhood ALL after treatment. Moreover, peripheral blood plasma DNA MRD can be an alternative where bone marrow
specimen is unavailable and as a less invasive method, which allows close monitoring.
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Introduction
Despite recent advances in the treatment of childhood acute
lymphoblastic leukemia (ALL), the disease remains a major cause
of cancer-related mortality in children. There are still around 20%
of patients who develop relapse, and those who survive suffer from
significant treatment related toxicities [1,2], which reflects both
under- or over-treatment of the disease as a result of the lack of
accurate assessment of the leukemic status. A better assessment
and particularly of patient’s risk of relapse at an early stage after
therapy, is thus needed to improve patient outcome. Convention-
ally, the initial peripheral blood (PB) and bone marrow (BM) blast
count, and the biological features of leukemic cells such as
karyotypic abnormalities and immunophenotypes, have been
adopted for risk stratification of ALL patients at diagnosis [3]. In
the recent decades, detection of minimal residual disease (MRD)
has become an important assessment and the level of MRD
emerged as one of the most powerful indicators of treatment
response in vivo, as it corresponds to the resistance of leukemic
cells to chemotherapy and also the dynamic interactions of
complicated therapy[4–6].
A variety of methods have been developed to detect MRD. The
most commonly used are PCR analysis of immunoglobulin/T-cell
receptor (Ig/TCR) gene rearrangements and flow cytometry
(FCM)[7–11]. The FCM method has the advantage over PCR of
providing a faster result and is more cost-effective and widely
applicable to most patients. It can also be applied in multi-center
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setting using standardized reagents and gating strategies [12,13].
Here we report our local findings as part of the I-BFM Mini-mini
project using FCM for quantitation of MRD [12], and determined
the clinically relevant MRD cutoffs for risk stratifying Chinese
patients treated under ALL IC-BFM 2002 protocol.
Development of novel methods for MRD detection, especially
by means of non-invasive sampling technique, provides an
alternative approach to determine early treatment response in
children. A number of studies have been done on the use of
detecting free circulating nucleic acids in blood plasma as a tool for
screening and disease monitoring of cancer patients[14–17]. BM is
still the major source of material needed for MRD studies in
childhood ALL, but the aspiration procedure is invasive for
children and frequent disease monitoring is not possible. In this
study, we evaluated the feasibility of MRD measurement on PB
plasma DNA for quantitative PCR, and determined the prognostic




Informed written consent for the study was obtained from all
patients’ parents/guardians, and the study was approved by the
Joint CUHK-NTEC Clinical Research Ethics Committee.
Patients
From January 2003 to April 2008, a total of 175 children (aged
1 to 18 years) diagnosed with ALL from 5 major hospitals in Hong
Kong were recruited in the ALL IC-BFM 2002 study [12].
Patients recruited from January 2003 to December 2004 (n = 67)
were assessed using 3-color panel and patients recruited from
January 2005 to December 2009 (n = 139) were assessed using 4-
color panel for FCM MRD. In addition 31 patients were recruited
into another study (ALL CCLG-2008) from May 2008 to
December 2009, and MRD was assessed using the same 4-color
FCM panel. Follow up data and survival status was obtained up to
August 2011. The median follow-up for survivors was 70.8 (ALL
IC-BFM 2002) and 26.0 months (ALL CCLG-2008). Clinical
characteristics of the patients were summarized in Table 1. The
BM and PB collection was performed at diagnosis, day 15 of
induction, end of induction phase I (day 33), and pre-consolidation
(week 12). FCM MRD prognostic analysis was performed on 113
patients at day 15 and 109 patients at day 33 with sufficient/
available BM materials.
Treatment
The treatment scheme for ALL IC-BFM 2002 protocol was
reported previously [12]. In brief, after 7-day steroid monotherapy
and one dose of intrathecal methotrexate (MTX), the patients
received 8-week induction and early intensification therapy.
Consolidation therapy consisted of high dose MTX and followed
by re-induction with combinations consisting dexamethasone,
vincristine, cyclophosphamide and anthracyclines. Cranial irradi-
ation was applied in high-risk and T-ALL patients only.
Maintenance therapy consisting of 6-mercaptopurine and MTX
then continued up to 24 months. The risk group was defined
according to standard BFM criteria, and MRD assessment was not
applied for risk stratification.
ALL CCLG-2008 was similar to the previous protocol, but
standard risk (SR) received a shortened early intensification
therapy and less intensive re-induction. Cranial irradiation was
applied only on patients with CNS disease or of very high risk not
planning for BM transplant. The study used NCI criteria together
with prednisone response for risk group stratification, and MRD
was employed to stratify patients.
Diagnostic Studies
The diagnosis of ALL was based on standard morphologic,
cytochemical, immunophenotypic and genetic studies. Flow
cytometric immunophenotyping of BM aspirates at diagnosis
was performed using a standard panel of antibodies (HLA-DR,
CD10, CD19, CD20, CD22, CD2, CD3, CD5, CD7, TdT,
CD13, CD14, CD33, MPO, CD41, CD16, CD34, CD79a,
glycophorin A, CD15) (Immunotech, France). The presence of
fusion genes including TEL/AML1, BCR/ABL and MLL/AF4
was examined by PCR and fluorescence in situ hybridization.
Conventional karyotyping was done using standard methods [18],
and the karyotypes were described according to the International
System of Human Cytogenetic Nomenclature [19].
Table 1. Summary of clinical and biological features for
patients in the study.
Treatment protocol ALL-IC-BFM 2002 ALL CCLG-2008
No. of patients 175 31
Median (range) Median (range)
Follow-up months 70.8 (36.8–101.7) 26.0 (17.2–36.8)
Age (years) 5.6 (1.1–17.9) 6.3 (1.2–16.8)
WBC (/1000 uL) 10.2 (0.7–673.8) 13.0 (1.5–384.5)
Frequency (%) Frequency (%)
Sex
male 105 (60.0) 17 (54.8)
female 70 (40.0) 14 (45.2)
Immunophenotype
common 99 (56.6) 17 (54.8)
early B 1 (0.6) 0 (0)
mature B 1 (0.6) 0(0)
pre-B 58 (33.1) 8 (25.8)
pro-B 2 (1.1) 0(0)
T/pre-T 14 (8.0) 6 (19.4)
ALL-IC-BFM 2002/CCLG-2008 risk group
standard risk 60 (34.3) 18 (58.1)
intermediate risk 91 (52.0) 8 (25.8)
high risk 24 (13.7) 5 (16.1)
Fusion genes
BCR/ABL 5 (2.9) 0 (0)
MLL/AF4 0 (0) 0 (0)
TEL/AML1 30 (17.1) 7 (24.1)
Day 8 prednisone response
good 160 (91.4) 26 (83.9)
poor 15 (8.6) 5 (16.1)
Outcome
Complete remission 155 (88.6) 29 (93.5)
Death in induction 2 (1.1) 2 (6.5)
Relapse 27 (15.4) 0 (0)
Bone marrow transplant 20 (11.4) 0 (0)
Death after induction 18 (10.3) 0 (0)
doi:10.1371/journal.pone.0069467.t001
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FCM MRD Analysis
Standardized operating procedures according to the Mini-mini
study were adopted for sample preparation, data acquisition, and
data analysis [12]. Leukemia-associated immunophenotypes
(LAIPs) were studied at diagnosis on erythrocyte-lysed BM samples
using the following antibody combinations: 3-color - CD19/
CD10/CD20, CD19/CD10/CD33, CD19/CD10/CD66c for B
lineage ALL; CD3/CD5/CD7 for T lineage ALL; 4-color -
CD58/CD10/CD19/CD34, CD20/CD10/CD19/CD34, and
CD66c/CD10/CD19/CD45 for B lineage ALL; CD99/CD7/
CD3/CD5 and CD7/sCD3/cyCD3/TdT for T lineage ALL (BD
Biosciences, San Jose, CA) (Immunotech). The same antibody
combinations were applied during follow up for MRD quantita-
tion. The strategy for MRD detection was based on detection of
cells expressing an aberrant immunophenotype including asyn-
chronous antigen expression and antigen overexpression com-
pared to normal BM. Data acquisition was performed with FC
500 cytometer (Beckman Coulter, Miami, FL) and FlowJo (Tree
Star, Ashland, OR) was used for data analysis. At least 20,000
events were acquired and analyzed for identification of aberrant
leukemic phenotypes at diagnosis, and at least 300,000 events were
needed for MRD measurements. A detection limit of 0.01% (10/
100,000 cells) could be achieved in most cases.
DNA Preparation and RQ-PCR MRD Analysis
Mononuclear cells (MNCs) from diagnostic BM samples were
obtained using Ficoll-Paque density centrifugation (GE Health-
care, Sweden). Plasma samples were collected from diagnostic and
follow-up PB. They were separated from PB within 24 hours after
collection by centrifugation (30006g, 10 minutes for 2 times).
Genomic DNA was isolated by QIAamp DNA Blood kit (Qiagen,
Germany) and QIAamp DNA Micro kit (Qiagen) for MNCs and
plasma samples respectively. For quantitation of total plasma DNA
and quality control in our samples, we performed beta-globin
quantitative PCR for all the plasma DNA samples using method
by Lo et al [20], and all samples have beta-globin being detected
with a median level of 332.51660.12 ng/ml. The input volume of
plasma (0.4–0.8 ml) and the elution volume (30 ul) of DNA were
standardized for later calculations.
The identification of PCR targets and RQ-PCR analysis were
described previously [9]. In brief, multiplex PCR was performed
using primers for detection of IgH, Igk, T-cell receptor c, and T-
cell receptor d gene rearrangements. Clonal bands were excised
and sequencing was performed with 31006L Genetic Analyzer
(Applied Biosystems, Foster City, CA). Patient-specific primers for
RQ-PCR were then designed according to the sequence analysis
using IMGT database (http://imgt.cines.fr, IMGT, European
Bioinformatics Institute, France). RQ-PCR was performed using
7300 real-time PCR system (Applied Biosystems). Five microliters
of plasma-extracted DNA was used in each of the 20 ul RQ-PCR
reactions, and performed in triplicates. DNA copy number of PB
plasma samples was computed according to standard curves by
serial dilutions of diagnostic BM samples. The sensitivity of plasma
DNA MRD was tested by spiking DNA at different concentrations
into plasma, then extracted DNA from these plasma samples and
performed RQ-PCR (Figure S1).
Statistical Analysis
Comparisons of categorical and continuous variables were
performed using Fisher’s exact test and Mann Whitney U test,
respectively. Risk of relapse or event-free survival (EFS) was
estimated with Kaplan-Meier analysis and log-rank test. Relapse
risk assessment was from the day of diagnosis to the occurrence of
relapse. EFS was measured from the day of diagnosis until failure
to achieve complete remission, transplant, relapse or death. Cox
regression analysis was performed to test for the significance of
MRD risk stratifications, controlling for potential prognostic
factors including age at diagnosis, sex, B or T lineage, white
blood cell count (WBC), hyperdiploidy, BCR-ABL translocation,
TEL-AML1 translocation, ALL-IC-BFM 2002 risk group, treat-
ment by bone marrow transplantation and day 8 prednisone
response. A p-value of ,0.05 was considered statistically




Identification for FCM MRD Monitoring
Three-color FCM MRD. We recruited 67 patients for 3-
color FCM MRD assessment, and 47 of them have available
sufficient marrow specimens for diagnostic/follow-up study. In 35
of the 43 of B-lineage ALL patients at diagnosis, a population of
leukemic cells could be identified by at least one LAIP, constituting
a coverage rate of 81.4% (35/43). Among these 35 patients of B-
ALL with positive LAIP, only 22.9% (8/35) had 2 or more while
the majority 77.1% (27/35) had only 1 LAIP identified for follow-
up. The most applicable antibody combination was CD19/
CD10/CD20 (62.9%, 22/35), followed by CD19/CD10/CD66c
(54.2%, 19/35), and CD19/CD10/CD33 (11.4%, 4/35). Single
tube was used in T-ALL (CD3/CD5/CD7) with a coverage rate of
100% (4/4).
Four-color FCM MRD. With an aim to improve the
coverage rate ($1 LAIP) and the accuracy (with $2 LAIPs for
each identifiable case) of MRD assessment, we switched to 4-color
panel of FCM MRD assessment on 139 patients (122 of them had
available BM material for MRD assessment). Although the
coverage rate for B-ALL (82.4%, 89/108) was very similar to
that obtained from 3-color panel, notably, there was a marked
improvement of MRD quantitation in that 84.3% (74/89) of these
patients had 2 or more LAIPs identified for follow up. For B-ALL,
both CD20/CD10/CD19/CD34 and CD66c/CD10/CD19/
CD45 were frequently expressed (74.2%, 66/89), and CD58/
CD10/CD19/CD34 was slightly less common (65.2%, 58/89).
Again, in T-ALL, the coverage rate was 100% and all patients
(14/14) had 2 LAIPs for follow-up (CD99/CD7/CD3/CD5 and
CD7/sCD3/cyCD3/TdT).
Correlation of FCM MRD and Clinical/Biological Factors
We compared the clinical and biological profiles of patients
assessed by 3-color and 4-color under ALL IC-BFM 2002 study
and found no statistically significant differences in age and sex
distribution, immunophenotypes, blood white cell counts, presence
of fusion genes, karyotypes, risk group, prednisone response and
treatment outcome (data not shown). Moreover, the proportions of
patients with MRD ,0.01% (3-color vs 4-color, Day33:63.9% vs
44.9%, Week 12:96.4% vs 81.7%) and their median MRD level at
all time points were also comparable (Day 15:0.13% Vs 0.19%,
Day 33: ,0.01% Vs ,0.01%, Week 12: ,0.01% Vs ,0.01%).
Thus the MRD data from these groups were pooled for the
prognostic analysis. However In the ALL CCLG-2008 study
assessed by 4-color panel, the median MRD level was higher (Day
15:0.64%, Day 33:0.56%). As this group of patients also had a
short follow up (26.0 months) we did not include them for the
prognostic analyses.
We then investigated the relationships of MRD levels at day 15
and day 33 among different clinical/biological factors (week 12
was not compared as most patients had MRD level below
MRD in Chinese Childhood ALL by FCM and Plasma DNA
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detection limit of 0.01%). In univariate analysis, we observed a
significant association of higher MRD level in T-lineage ALL
patients (day 15: p,0.001, day 33: p,0.001), ALL IC-BFM 2002
high risk group (day15: p,0.001, day33: p = 0.001), patients with
poor day 8 prednisone response (day15: p,0.001, day 33:
p,0.001), non-hyperdiploid ALL (day 15: p = 0.031, day 33:
p,0.001), age .6 years (day15: p,0.001, not significant for day
33), and WBC .20000/ul (day 15: p = 0.049, not significant for
day 33) (Figure S2).
Determination of Clinically Relevant FCM MRD Cutoffs at
Day 15 and Day 33
We divided the patients into high MRD ($cutoff) or low MRD
(,cutoff) groups according to different cutoffs and looked into
their relationships with the relapse rate. As shown in Table 2,
MRD.0.1% at day 15 showed some predictive value for relapse
(p = 0.042) which improved at higher MRD cutoffs MRD.1%
and MRD.10% (p = 0.001 and p,0.001 respectively). At day 33,
patients with MRD level higher than 0.01% also had a
significantly higher relapse rate (p = 0.004), but the specificity
(64.0%) in predicting patients in remission by Day 33 MRD
,0.01% was lower than that by using the cutoff of 1% or 10% at
day 15 (74.4% and 92.2% respectively) (Table 2). An analysis of
outcome according to levels of MRD on day 33 only was also
shown (Figure S3).
Superior Risk Prediction by FCM MRD Stratification Based
on Both Day 15 and Day 33 MRD Values (Model II)
To apply the risk stratification scheme based on FCM MRD, we
stratified the patients into three risk groups (I-A: ,0.1%, I-B: 0.1–
10%, I-C: .10%) according to MRD measured at day 15 (Model
I). We found patients with high-level MRD (I-C) (n = 18, 15.9%)
were significantly associated with low EFS and high incidence of
relapse compared to those with intermediate MRD (I-B) (n = 47,
41.6%) and low MRD (I-A) (n = 48, 42.5%). The 5-year EFS and
5-year incidence of relapse for I-A vs I-B vs I-C were 89.1% vs
78.7% vs 38.9% (p,0.0001) and 8.7% vs 13.3% vs 37.5%
(p = 0.0047) respectively (Figure 1, upper left and right).
As day 33 MRD.0.01% was highly predictive of relapse in the
previous determination, to refine the risk stratification scheme
based on FCM MRD, we designed another MRD risk group
stratification (Model II) based on both day 15 and day 33 MRD
values (II-A: day 15,10% and day 33,0.01%; II-B: day 15$10%
or day 33$0.01% [but not both]; II-C: day 15$10% and day
33$0.01%). Likewise, patients with high MRD at both time points
(II-C) (n = 13, 11.9%) had worse outcome compared to those who
only had MRD above cutoff at one time point (II-B) (n = 35,
32.1%) or had both below cutoff (II-A) (n = 61, 56.0%), as
evidenced by the 5-year EFS (II-A vs II-B vs II-C: 90.1% vs 71.4%
vs 46.2%) (p = 0.0002) and 5-year incidence of relapse (II-A vs II-B
vs II-C: 6.8% vs 20.6% vs 53.8%) (p,0.0001) (Figure 1, lower left
and right). Comparing the figures of 5-year EFS and relapse rates
from the two models, Model II showed superior prediction and
better segregation of patients with different risks of relapse/
survival.
Significant Prognostic Impact of FCM MRD within B-
lineage ALL Patients and ALL IC-BFM 2002-stratified Risk
Groups
We further assessed the predictive value of FCM MRD by
excluding T-lineage ALL patients which generally had poorer
treatment outcomes. As illustrated in Figure 2A, both Model I and
II maintained significant prognostic impact (p,0.0001 for both)
by identifying patients with differential outcomes. In high risk (I-C
and II-C) patients, the 5-year relapse rates were 63.6% and 75.0%
respectively; whereas in low risk group (I-A and II-A), the rates
were only 6.8% and 7.0%.
In ALL IC-BFM 2002 risk group classification, MRD values
were not used as patient stratification criterion; thus it is of interest
to assess the predictive value of MRD in these conventional risk
groups. As shown in Figure 2B, patients originally defined as ALL
IC-BFM 2002- Standard risk (SR) and intermediate risk (IR) could
be further stratified by the FCM MRD models (high risk patients
Table 2. Prognostic significance of FCM MRD at different cutoffs.










Day 15:10% $10% 7 (7.8%) 9 (47.4%) 47.4% 92.2% 56.3% 89.2% ,0.001
,10% 83 (92.2%) 10 (52.6%)
Day 15:1% $1% 23 (25.6%) 13 (68.4%) 68.4% 74.4% 36.1% 91.8% 0.001
,1% 67 (74.4%) 6 (31.6%)
Day 15:0.1% $0.1% 47 (52.2%) 15 (78.9%) 78.9% 47.8% 24.2% 91.5% 0.042
,0.1% 43 (47.8%) 4 (21.1%)
Day 15:0.01% $0.01% 71 (78.9%) 16 (84.2%) 84.2% 21.1% 18.4% 86.4% NS
,0.01% 19 (21.1%) 3 (15.8%)
Day 33:1% $1% 5 (5.6%) 2 (10.5%) 10.5% 94.4% 28.6% 83.2% NS
,1% 84 (94.4%) 17 (89.5%)
Day 33:0.1% $0.1% 19 (21.3%) 8 (42.1%) 42.1% 78.7% 29.6% 86.4% NS
,0.1% 70 (78.7%) 11 (57.9%)
Day 33:0.01% $0.01% 32 (36.0%) 14 (73.7%) 73.7% 64.0% 30.4% 91.9% 0.004
,0.01% 57 (64.0%) 5 (26.3%)
doi:10.1371/journal.pone.0069467.t002
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were not analyzed due to small sample size): For Model I, the 5-
year incidence of relapse was 8.0% (I-A), 18.2% (I-B), and 100.0%
(I-C) in BFM-SR (p = 0.0002); and 10.0% (I-A), 11.5% (I-B) and
66.7% (I-C) respectively in BFM-IR (p,0.0001). For Model II, the
incidence was 11.4% (II-A), 15.4% (II-B), and 100.0% (II-C) in
BFM-SR (p = 0.0029); and 3.2%, 28.6% and 66.7% in BFM-IR
respectively (p,0.0001) (Figure 2B).
PB Plasma DNA for MRD Monitoring: Feasibility and
Prognostic Value
To assess the feasibility of MRD monitoring using DNA from
PB plasma, we performed the quantitation of Ig/TCR gene
rearrangements on plasma samples collected at day 15, day 33 and
week 12 of treatment. Most samples collected at day 33 and week
12 had MRD below detection limit of 1025 and were not analyzed
further. We first compared the data of PB plasma DNA MRD
with FCM MRD as shown in Figure 3A. Of 63 cases with
available data for both MRD detection methods, only 35 of them
(55.6%) were defined as MRD-positive/negative by both FCM
(cutoff: 0.01%) and plasma DNA MRD (cutoff: 1025). The 2
methods did not yield significant correlations in MRD levels (R2:
20.0733).
We then analyzed PB plasma DNA MRD data independently
for its prognostic value. A significant correlation of day 15 MRD
levels with the incidence of relapse was observed (n = 78, p = 0.04),
in which the patients who eventually relapsed had a median MRD
level of 4.2661023, compared to ,1025 in patients undergoing
remission. The relationship of plasma DNA MRD data with
clinical and biological profiles was also studied, but no significant
association was observed (data not shown). To define an
appropriate cutoff with prognostic significance, we again analyzed
the data by dividing the patients into high or low MRD groups at
MRD levels from 1022 to 1025 (Table 3). Cutoffs from 1023 to
1025 could significantly differentiate patients who developed
relapse (sensitivity: 70.0–80.0%) and who were in remission
(specificity: 58.8–67.6%), where the best cutoff was 1024
(p = 0.018).
Using the cutoff at 1024, patients with high MRD (n = 34)
was associated with poorer 5-year EFS (64.5%) and higher
incidence of relapse (24.6%) compared to patients with low
MRD (n = 44) (EFS: 91.3%, relapse rate: 4.5%) (p = 0.0039 and
p = 0.0117 respectively) (Figures 3B and C). It maintained a
significant prognostic impact also in patients with B-lineage
ALL, or within ALL IC-BFM-2002 SR and IR groups analyzed
separately. In patients with B-lineage ALL the relapse rate was
Figure 1. Prognostic significance of MRD as detected by FCM at day 15 and day 33. Event-free survival (left) and incidence of relapse
(right) of patients stratified according to FCM MRD Model I (upper panel) and Model II (lower panel).
doi:10.1371/journal.pone.0069467.g001
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24.7% for patients with MRD $1024 (n = 73) and 4.7% for
those with MRD ,1024 (p = 0.0152)(Figure 3D). For the BFM-
SR group (n = 24) (Figure 3E), 33.3% with MRD $1024
relapsed versus 0% in MRD ,1024 (p = 0.0331); and in BFM-
Figure 2. Prognostic significance of FCM MRD for patients with selected features. Incidence of relapse for patients with (A) B-lineage ALL
(B) in ALL IC-BFM 2002 standard risk (left) or intermediate risk (right). Upper panels were stratified by Model I and lower panels were by Model II.
doi:10.1371/journal.pone.0069467.g002
MRD in Chinese Childhood ALL by FCM and Plasma DNA
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IR (n = 42) (Figure 3F), the relapse rate was 28.6% vs 7.1%
respectively (p = 0.0526).
Multivariate Analyses of MRD Risk Stratification by FCM
and PB Plasma PCR
The significance of MRD by FCM, and PCR using plasma
DNA for predicting relapse was tested in Cox regression analyses
(Table 4). Parameters included in the models with potential
prognostic effect were age at diagnosis, sex, B or T lineage, WBC,
hyperdiploidy, BCR-ABL translocation, TEL-AML1 transloca-
tion, ALL-IC-BFM 2002 risk group, day 8 prednisone response,
and bone marrow transplantation (BMT). FCM MRD Models I
and II, and PB plasma MRD at 1024 on day 15 remained
significant even after controlling for all the prognostic factors.
Notably, patients having high-level FCM MRD had approxi-
mately 20 to 35-fold increase (p,0.001) in the risk of relapse, and
those having plasma MRD of $1024 had a 5.8 fold higher risk of
relapse (p = 0.038).
Discussion
MRD detection has become an essential tool for assessment of
in vivo treatment response in childhood ALL and FCM is one of
the most commonly used technologies, which is easy to apply and
with fast available results. The standardization of FCM MRD
method which has taken place in several centers has demonstrated
reproducibility with a good correlation to patient’s treatment
outcome[12,13,21–23], thereby favoring its application in multi-
center studies.
Our study was also derived from a multicenter international
collaboration using standardized methodology of FCM MRD
(Mini-mini study). We previously demonstrated the feasibility of
uniform method for FCM MRD detection applied in multi-centers
[12]. Here we presented our local data and extended our
observations on its relationships to treatment outcome. We
established two MRD risk stratification strategies, one using
MRD data from single time point at day 15 (Model I) and the
other using two time points at day 15 and day 33 (Model II).
Patients could be stratified according to FCM MRD risk groups,
with a significantly high incidence of relapse for group I-C and II-
C (37.5% and 53.8%) but only 8.7% and 6.8% in I-A and II-A.
Both models were still applicable if cases with known risk factors
were removed (T-lineage ALL, ALL IC-BFM 2002 high risk). In
particular, our FCM MRD risk stratifications were the most
potent prognostic factors among all the conventional indicators
and BM PCR MRD (unpublished in-house data).
Our findings were in line with those from other prognostic
studies on FCM MRD. The Children’s Oncology Group showed
that in patients positive ($0.01%) for day-29 (end-of-induction)
MRD was associated with poorer outcome (p,0.0001) compared
to those with negative MRD, and day-29 MRD was the
independent prognostic variable in multivariate analysis [24].
The group from St. Jude’s Children’s Research Hospital studied
day-19 of induction therapy and showed that patients with
$0.01% residual leukemic cells had significantly higher incidence
of relapse/failure to achieve remission than those with undetect-
able leukemic cells (p,0.001) [10]. A recent AIEOP-BFM-ALL
2000 study, using similar treatment regimens and antibody panels
with ours, stratified similar risk groups according to FCM MRD at
day 15 as our Model I and found significant difference in
incidences of relapse among the 3 risk groups (p,0.001). The risk
groups were also found to be the most potent prognostic factor in
multivariate analysis, with 2 to 5-fold increases in risk of relapse for
patients classified into medium and high risk groups [21]. In
addition to these similar findings, we demonstrated the prognostic
impact of another FCM MRD risk stratification strategy using
MRD results from two time points (Model II). This model
provided a better discrimination of patients than FCM Model I
stratification with significantly increasing risk of relapse in higher
risk groups (II-A vs B vs C: 6.8% vs 20.6% vs 53.8%) (p,0.0001),
which may better reflect the status of leukemic cell clearance as
MRD at both time points were considered. Furthermore, Model II
could better identify patients with good outcomes. The I-A and II-
A have similarly good EFS (89.1% and 90.1%) but the percentage
of patients being in good risk increased from 48/113 (42.5% by
Model I) to 61/109 (56.0% by Model II), indicating that more
patients could be accurately predicted to have good outcome and
may benefit from reduced treatment intensity. In conclusion, both
Model I and II have similar specificities in identifying good risk
patients (IA or IIA). However, Model II has a higher sensitivity to
identify these good risk patients (IIA) and these patients had been
mis-classified as intermediate risk (IB) or to a lesser extent, as high
risk (IC) in Model I. It would thus be advisable that group IB or IC
patients (by Model I) should be tested beyond day 15 for more
accurate risk classification by Model II.
With the stratification based on ALL IC-BFM 2002 (Figure 2B),
the Model II could not further refine the risk groups in SR
patients, as the incidence of relapse were similar in both I-A versus
II-A and I-B versus II-B, and the percentage of patients distributed
in the 3 risk groups in Model I and II were also similar in SR.
However, the Model II had a significant effect on relapse
prediction in IR group. Model II identified low risk patients with
only a 3.2% relapse rate compared to a 10% rate in Model I.
More importantly, the percentage of patients in IR predicted to
have good outcome increased from 20/52 (38.5% by Model I) to
31/51 (60.8% by Model II). We could also identify a subset of IR
patients with higher risk of relapse by Model II (II-B with 28.6%
versus I-B with 11.5%), and this may justify further intensification
of treatment in this subset of patients. Thus, the Model II
prediction might benefit the BFM IR group but may not be
beneficial to SR group.
It is interesting that we found the applicability of antibody
combinations were different with other reported studies. Aberrant
expression of CD66c was observed in 43% of European patients
and 10–20% of Americans [10,25], but it was more frequently
expressed in our cohort (54.2% for 3-color and 74.2% for 4-color).
CD58 was overexpressed in only 33.3% of patients in Patkar’s
study [26], but we found more frequent aberrant expression at
65.7%. Similar frequency was found in CD10-CD20 combina-
tions (71.4% by Patkar et al [26] and 62.9–74.2% by us). Thus,
our observations suggested that the usefulness of antibody
combinations may depend on patient’s ethnic group, and
evaluation of antibodies for MRD detection should be done
independently in each center. Besides, the coverage rate of FCM
MRD for B-lineage ALL patients was around 80%, which was less
desirable compared to the other studies with .90%(10–11).
Figure 3. Prognostic significance of MRD as detected by PB plasma DNA PCR at day 15. (A) Correlation of PB plasma DNA MRD with FCM
MRD at day 15. Spearman r test was used for statistical analysis. (B–C) Comparison of PB plasma DNA MRD level (cutoff: 1024) at day 15 with (B) event-
free survival and (C) occurrence of relapse. (D–F) Incidence of relapse for patients stratified according to PB plasma MRD cutoff at 1024 with (D) B-
lineage ALL, in ALL IC-BFM 2002 standard risk (E) or intermediate risk (F).
doi:10.1371/journal.pone.0069467.g003
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Therefore, we currently adopted an extended panel of antibodies
to aim for a better applicability of FCM MRD to most patients,
and our preliminary results showed an improvement of coverage
to .95% (unpublished data).
In the second part of the study, we evaluated a non-invasive
method of MRD detection using PB plasma for PCR. This is, to
our knowledge, the first study to quantify Ig/TCR gene
rearrangements in PB plasma DNA of childhood ALL patients
by adopting the technique on BM to PB plasma DNA. A few
studies have attempted to use plasma DNA for MRD detection,
but they were limited to measure the concentration of plasma
DNA or to detect the PCR products qualitatively [27,28]. In fact,
detection of circulating DNA in blood plasma has been studied in
various cancers for early cancer detection and disease monitor-
ing[14–17]. It was postulated that the origin of these circulating
DNA was derived from tumor necrosis and apoptosis, and high
concentrations of plasma DNA was found to be correlated to the
larger tumor size and advanced diseases [29]. We found poor
correlations of MRD levels by plasma DNA and FCM, which can
be explained by the difference in source material being analyzed
(PB cell-free DNA vs BM cells), and different leukemic targets
being detected/quantified (with clonal IgH/TcR vs aberrant
antigen expression). Nevertheless, both methods can independent-
ly predict relapse as demonstrated by multivariate analysis. The
results of our study not only supported the idea and feasibility of
using PB plasma DNA as a tool for treatment monitoring in
leukemia patients, we also demonstrated the prognostic impact of
PB MRD. Thus, MRD results from plasma DNA can be applied
where BM specimens are not available, or for more frequent
disease monitoring without the need for BM aspiration.
In this study, we have established MRD risk stratification
strategies for Chinese childhood ALL patients under ALL IC-
BFM 2002 protocol. The potential role of using PB plasma DNA
as a non-invasive tool for MRD monitoring was also demonstrat-
ed. Further studies with larger patient cohort and earlier time
points are warranted to clarify the clinical significance of using
plasma DNA as an alternative tool for MRD monitoring.
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